前列腺癌商业基因表达检测的区域采纳差异
该动态队列研究利用美国商业医保索赔数据,分析2012-2018年前列腺癌患者组织基因组检测的区域采纳轨迹,发现检测比例从0.8%升至11.3%,并识别出5种区域轨迹,最高组达33.8%,且高采纳区域与更高教育、收入及医疗资源相关。
要点
- 前列腺癌基因组检测使用率从2012-2013年的0.8%增至2017-2018年的11.3%。
- 区域采纳轨迹分为5组,最高组检测比例达33.8%,最低组仅4.0%。
- 高采纳区域与更高的教育水平、家庭收入及前列腺癌医疗资源相关。
核心结论
- 商业组织基因组检测在美国区域间采纳差异很大,可能与社会经济地位和前列腺癌诊疗模式相关。
主要发现
- 总体检测比例从2012年7月-2013年6月的0.8%上升至2017年7月-2018年6月的11.3%。
- 轨迹模型识别出5种区域采纳轨迹,基线时各组检测比例均不足1%。
- 最低采纳组(组1)检测比例增至4.0%,组2、3、4分别增至7.8%、14.6%、17.3%,最高采纳组(组5)增至33.8%。
临床怎么用
- 临床医生应了解所在区域基因组检测采纳模式差异,在决策中结合区域资源与患者社会经济因素。
局限性
- 研究基于商业保险索赔数据,可能未覆盖无保险或其他支付方式患者。
- 区域特征比较使用既往Medicare受益人数据,可能存在生态学偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although tissue-based genomic tests can aid in treatment decision-making for patients with prostate cancer, little is known about their clinical adoption. OBJECTIVE: To evaluate regional adoption of genomic testing for prostate cancer and understand common trajectories of uptake shared by regions. DESIGN, SETTING, AND PARTICIPANTS: This dynamic cohort study of patients diagnosed with prostate cancer used administrative claims from Blue Cross Blue Shield Axis, the largest source of commercial health insurance in the US, to characterize temporal trends in the use of commercial, tissue-based genomic testing and calculate the proportion of tested patients at the hospital referral region (HRR) level. Eligible patients from July 1, 2012, through June 30, 2018, were those aged 40 to 89 years with prostate cancer diagnosed from July 1, 2012, through June 30, 2018. MAIN OUTCOMES AND MEASURES: Group-based trajectory modeling was used to classify regions according to discrete trajectories of adoption of commercial, tissue-based genomic testing for prostate cancer. Across regions with distinct trajectories, HRR-level sociodemographic and health care contextual characteristics were compared, using data previously calculated among Medicare beneficiaries. RESULTS: A total of 92 418 men with prostate cancer who met inclusion criteria were identified; the median (interquartile range) age at diagnosis was 60 (56-63) years. Overall, the proportion of patients who received genomic testing increased from 0.8% in July 2012 to June 2013 to 11.3% in July 2017 to June 2018. Trajectory modeling identified 5 distinct regional trajectories of genomic testing adoption. Although less than 1% of patients in each group were tested at baseline, group 1 (lowest adoption) increased to 4.0%. Groups 2 (7.8%), 3 (14.6%), and 4 (17.3%) experienced more modest growth, while in group 5 (highest adoption), use increased to 33.8% of patients tested from June 2017 to July 2018. Compared with regions that more slowly adopted testing, HRRs with the highest rate of adoption (group 5) had higher HRR-level education measures (percentage [SD] with college education: group 1, 25.6% [4.8%]; vs group 2, 27.5% [7.3%]; vs group 3, 30.3% [9.1%]; vs group 4, 29.8% [8.2%]; vs group 5, 30.4% [11.4%]; P for trend = .03), median (SD) household income (group 1, $50 412.8 [$6907.4]; vs group 2, $54 419.6 [$11 324.5]; vs group 3, $61 424.0 [$17 723.8]; vs group 4, $58 508.3 [$15 174.6]; vs group 5, $58 367.0 [$13 180.5]; P for trend = .005), and prostate cancer resources, including clinician density (No. [SD] of clinicians per 100 000: group 1, 2.5 [0.3]; vs group 2, 2.5 [0.5]; vs group 3, 2.6 [0.5]; vs group 4, 2.7 [0.7]; vs group 5, 2.6 [0.5]; P for trend = .04) and prostate cancer screening (percentage [SD] of prostate-specific antigen testing among patients aged 68-74 y: group 1, 29.4% [11.8%]; vs group 2, 32.4% [11.2%]; vs group 3, 33.1% [12.7%]; vs group 4, 36.1% [9.7%]; vs group 5, 28.8% [11.8%]; P for trend = .05). CONCLUSIONS AND RELEVANCE: In this cohort study of patients with prostate cancer, the adoption of commercial tissue-based genomic testing for prostate cancer was highly variable in the US at the regional level and may be associated with contextual measures related to socioeconomic status and patterns of prostate cancer care. These findings highlight factors underlying differential adoption of prognostic technologies for patients with cancer.
引用
- Leapman MS, Wang R, Ma S, et al. Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer. JAMA Oncol. 2021. PMID: 33237277. doi:10.1001/jamaoncol.2020.6086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。